Dichotic Listening as a Predictor of Medication Response in Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Major Depressive DisorderDysthymia
Interventions
DRUG

escitalopram

Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d

DRUG

bupropion

bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d

DRUG

imipramine

imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER

NCT00404755 - Dichotic Listening as a Predictor of Medication Response in Depression | Biotech Hunter | Biotech Hunter